Key facts
- It has raised $3.0M; the latest was Grant ($1.9M) in May 2025.
- Notable investors include Key Ventures, Ministry of Research, iXCore.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for QUIDDITAS
- ·The full record, as it builds
Funding rounds
No funding rounds for QUIDDITAS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About QUIDDITAS
Developer of a genome editing-based therapy designed for genetic disorders, oncology, and organ transplants. The company's technology allows absolute genetic recombination to receive therapeutic responses to diseases considered incurable through off-the-shelf treatments, enabling healthcare professionals to treat genetic disorders.
- Sector
- Healthcare
- HQ
- Montlhery, France
- Founded
- 2022
- Employees
- 4
- Website
- quidditastherapeutics.com/
- Ownership
- Privately Held (backing)
QUIDDITAS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in QUIDDITAS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on QUIDDITAS in its N-PORT filings yet. We sweep new filings monthly.